AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25069201 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture stimulation of TE 5 combined with routine acupuncture and rehabilitation training (30 min, once daily)
Number of subjects: 60
Study 25069201 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture stimulation of the same acupoints and rehabilitation training (30 min, once daily)
Number of subjects: 60
Study 21618513 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lignan intake (highest vs. lowest lignan intake quartile)
Number of subjects: 1859
Study 21618513 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lignan intake
Number of subjects: 1859
Study 21618513 — intervention group
Group type: COMPARATOR
Intervention: Individual or total lignans or proanthocyanidins
Number of subjects: 1859
Study 19237895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)-induced pulsatile CPB (group B)
Number of subjects: 80
Study 19237895 — intervention group
Group type: COMPARATOR
Intervention: Conventional linear CPB (group A)
Number of subjects: 80
Study 17289685 — intervention group
Group type: EXPERIMENTAL
Intervention: Three months of anticoagulation with heparin for five days followed by warfarin (n=369)
Number of subjects: 749
Study 17289685 — intervention group
Group type: COMPARATOR
Intervention: Six months of anticoagulation with heparin for five days followed by warfarin (n=380)
Number of subjects: 749
Study 17289685 — intervention group
Group type: EXPERIMENTAL
Intervention: Three months of anticoagulation
Number of subjects: 749
Study 17289685 — intervention group
Group type: COMPARATOR
Intervention: Six months of anticoagulation
Number of subjects: 749
Study 15461621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone combined with melphalan (MD)
Number of subjects: 201
Study 15461621 — intervention group
Group type: COMPARATOR
Intervention: Melphalan-prednisone (MP)
Number of subjects: 201
Study 11413078 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (200 microgram/d)
Number of subjects: 12
Study 11413078 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated estrogens (0.625 mg/d)
Number of subjects: 12
Study 11413078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11413078 — intervention group
Group type: COMPARATOR
Intervention: Intravenous conjugated estrogens
Number of subjects: 12
Study 11413078 — intervention group
Group type: COMPARATOR
Intervention: Sublingual estradiol
Number of subjects: 12
Study 9641731 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH) treatment at a dosage of 0.2 IU/kg/body weight (0.067 mg/kg) subcutaneously daily for 3 years.
Number of subjects: 69
Study 9641731 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2) with a 1-year observation period followed by a 3-year treatment period.
Number of subjects: 69
Study 7557720 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management services with legal stipulations as a condition of probation and parole
Number of subjects: 51
Study 7557720 — intervention group
Group type: COMPARATOR
Intervention: Case management services without legal stipulations (implied control)
Number of subjects: 51
Study 2363027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity TENS (3 times the sensory threshold, frequency of 100 Hz)
Number of subjects: 60
Study 2363027 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity TENS (at the sensory threshold, frequency of 100 Hz)
Number of subjects: 60
Study 2363027 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 60
Study 6781189 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administered at an early stage
Number of subjects: 26
Study 6781189 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administered at a late stage
Number of subjects: 26
Study 31124839 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual bolus atomization of bupivacaine (1.25 mg/kg diluted in 30 mL normal saline over 30 seconds)
Number of subjects: 67
Study 31124839 — intervention group
Group type: COMPARATOR
Intervention: Micropump nebulization of bupivacaine (0.5% undiluted over 10-17.4 minutes)
Number of subjects: 67
Study 31124839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both delivery methods
Number of subjects: 67
Study 27348314 — intervention group
Group type: COMPARATOR
Intervention: Limbal-based conventional AGV along-with PK
Number of subjects: 58
Study 27348314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars-plana-modified AGV along-with PK
Number of subjects: 58
Study 26357864 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (25 μg or 50 μg twice daily for 9 weeks)
Number of subjects: 120
Study 24327720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (1,000 IU/day)
Number of subjects: 328
Study 24327720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 IU/day)
Number of subjects: 328
Study 24327720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4,000 IU/day)
Number of subjects: 328
Study 24327720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 23187322 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration on contracted quadriceps (VC)
Number of subjects: 18
Study 23187322 — intervention group
Group type: COMPARATOR
Intervention: Vibration on relaxed muscle (VR)
Number of subjects: 18
Study 23187322 — intervention group
Group type: COMPARATOR
Intervention: Sham vibration (NV)
Number of subjects: 18
Study 21146661 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (500 mg aspirin, 600 mg clopidogrel, and tirofiban 25 μg/kg bolus and 0.15 μg/kg per minute maintenance infusion for 18 hours)
Number of subjects: 1398
Study 21146661 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy
Number of subjects: 1398
Study 21146661 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (500 mg aspirin and 600 mg clopidogrel)
Number of subjects: 1398
Study 17549878 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoneme training group (P)
Number of subjects: 83
Study 17549878 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllable training group (S)
Number of subjects: 83
Study 17549878 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset-rime training group (OR)
Number of subjects: 83
Study 17549878 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-word training group (WW)
Number of subjects: 83
Study 17549878 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 83
Study 15860853 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐OHT gel (0.5, 1, or 2 mg/d)
Number of subjects: 55
Study 15860853 — intervention group
Group type: COMPARATOR
Intervention: Oral tamoxifen (20 mg/d)
Number of subjects: 55
Study 15860853 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 55
Study 12475151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of Rifater (RFT)/Rifinah (RFN)
Number of subjects: 105
Study 12475151 — intervention group
Group type: COMPARATOR
Intervention: Separate regimen of four component drugs (INH, RMP, EMB, PZA)
Number of subjects: 105
Study 10561143 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Gelatin Capsule (SGC) formulation
Number of subjects: 20
Study 10561143 — intervention group
Group type: COMPARATOR
Intervention: Oral solution formulation
Number of subjects: 20
Study 7635420 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 42
Study 7635420 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 42
Study 7635420 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 42
Study 2237981 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (carotid endarterectomy)
Number of subjects: 3200
Study 2237981 — intervention group
Group type: COMPARATOR
Intervention: Medical intervention
Number of subjects: 3200
Study 1071698 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (chlorothiazide + alpha-methyldopa and/or a beta-adrenoreceptor antagonist as required)
Number of subjects: 4000
Study 1071698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 1071698 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial endpoints (death, morbidity from stroke, hypertensive heart and renal disease, and ischaemic heart disease)
Number of subjects: 4000
Study 30657576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (TUDCA)
Number of subjects: 60
Study 29138555 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine beclomethasone dipropionate plus formoterol fumarate (BDP-FF)
Number of subjects: 0
Study 29138555 — intervention group
Group type: COMPARATOR
Intervention: Formoterol fumarate (FF)
Number of subjects: 0
Study 26265639 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual small‐incision cataract surgery (MSICS)
Number of subjects: 52
Study 26265639 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification (PE)
Number of subjects: 52
Study 21957933 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 88
Study 21957933 — intervention group
Group type: COMPARATOR
Intervention: Guided self-help or e-mail therapy (original trial)
Number of subjects: 88
Study 21257118 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session standardized program based on the comprehensive social influence model
Number of subjects: 7079
Study 21257118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7079
Study 19916211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 60
Study 19916211 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 60
Study 19916211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16972972 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely early enteral feeding (breast milk within 24 hours after birth)
Number of subjects: 21
Study 16972972 — intervention group
Group type: COMPARATOR
Intervention: Control group (breast milk more than 24 hours after birth)
Number of subjects: 21
Study 14735178 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox28 (72% He/28% O(2))
Number of subjects: 12
Study 14735178 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-enriched air (72% N(2)/28% O(2))
Number of subjects: 12
Study 14735178 — intervention group
Group type: COMPARATOR
Intervention: Medical air (78.9% N(2)/21.1% O(2))
Number of subjects: 12
Study 11759742 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 30
Study 11759742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9159346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis (500 mg orally twice a day)
Number of subjects: 90
Study 9159346 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 90
Study 9159346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis
Number of subjects: 90
Study 7567400 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instruction
Number of subjects: 60
Study 7567400 — intervention group
Group type: COMPARATOR
Intervention: Evaluative instruction
Number of subjects: 60
Study 2816477 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives for 30 days
Number of subjects: 0
Study 2816477 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives for 15 days
Number of subjects: 0
Study 2816477 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressed cycles
Number of subjects: 0
Study 808126 — intervention group
Group type: EXPERIMENTAL
Intervention: Keflex and Keflin (therapeutic doses)
Number of subjects: 60
Study 808126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (a silencing RNA that inhibits PCSK9 synthesis)
Number of subjects: 0
Study 31449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen (an antisense oligonucleotide targeting apoB)
Number of subjects: 0
Study 31449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen (APOC3) and ANGPTL3-LRx
Number of subjects: 0
Study 28851933 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml/kg/min ELO‐MEL‐isoton (osmolarity = 302 mosmol/l) for 60 minutes
Number of subjects: 15
Study 28851933 — intervention group
Group type: COMPARATOR
Intervention: Nothing at all (control group)
Number of subjects: 15
Study 26299520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once-daily
Number of subjects: 1498
Study 26299520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1498
Study 23250996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 165
Study 23250996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 22161694 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg daily for 14-17 days)
Number of subjects: 30
Study 22161694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19636163 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrum(R)
Number of subjects: 1020
Study 19636163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study 16784965 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium-containing milk powder (200 microg/20 g milk powder) twice a day for 16 weeks
Number of subjects: 60
Study 16784965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15572756 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg) and retinyl palmitate (25,000 IU)
Number of subjects: 18314
Study 15572756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18314
Study 11230889 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy, 100% oxygen for 100 min in a multiplace hyperbaric chamber on 30 occasions over a period of 6 weeks.
Number of subjects: 34
Study 11230889 — intervention group
Group type: COMPARATOR
Intervention: Control group, breathing a gas mixture equivalent to breathing 100% oxygen at surface pressure.
Number of subjects: 34
Study 9425965 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg bupivacaine
Number of subjects: 90
Study 9425965 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg bupivacaine
Number of subjects: 90
Study 9425965 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg bupivacaine
Number of subjects: 90
Study 9425965 — intervention group
Group type: COMPARATOR
Intervention: Control (spinal lidocaine)
Number of subjects: 90
Study 8516653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily
Number of subjects: 29
Study 8516653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2850326 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfa LMW1 (8,000 I.U. AXa daily for 6 months)
Number of subjects: 55
Study 2850326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31819201 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia training (FiO2 15%)
Number of subjects: 23
Study 31819201 — intervention group
Group type: COMPARATOR
Intervention: Ambient conditions (FiO2 21%)
Number of subjects: 23
Study 30496229 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool staff's average activity levels during preschool hours
Number of subjects: 289
Study 30496229 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool staff's attitudes
Number of subjects: 289
Study 30496229 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool staff's initiative
Number of subjects: 289
Study 30496229 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool staff's participation
Number of subjects: 289
Study 28361576 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking group (BWG)
Number of subjects: 30
Study 28361576 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate tempo walking group (MTWG)
Number of subjects: 30
Study 28361576 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 26182387 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced education by telephone
Number of subjects: 390
Study 26182387 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced education by SMS
Number of subjects: 390
Study 26182387 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced education groups (telephone and SMS combined)
Number of subjects: 390
Study 26182387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 390
Study 23764248 — intervention group
Group type: EXPERIMENTAL
Intervention: CT number-controlling system (CTN-CS) for determining contrast amount based on body surface area and peak CT number
Number of subjects: 172
Study 23764248 — intervention group
Group type: COMPARATOR
Intervention: Same amount of intravenous contrast in both CCTA examinations
Number of subjects: 172
Study 23764248 — intervention group
Group type: COMPARATOR
Intervention: 0.7 mL/mg body weight of contrast medium (350 mgI/mL) for baseline and follow-up CCTAs
Number of subjects: 172
Study 21992655 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) for 10 weeks, guided by an online therapist, focusing on acceptance of symptoms through exposure and mindfulness training.
Number of subjects: 61
Study 21992655 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group for 10 weeks.
Number of subjects: 61
Study 21992655 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT group at 12-month follow-up.
Number of subjects: 61
Study 21992655 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness of ICBT compared to waiting list control.
Number of subjects: 61
Study 17521776 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 0
Study 17521776 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (in normal human peripheral blood mononuclear cell cultures)
Number of subjects: 0
Study 17176013 — intervention group
Group type: EXPERIMENTAL
Intervention: X STOP Interspinous Process Decompression (IPD) System
Number of subjects: 0
Study 17176013 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative therapies
Number of subjects: 0
Study 14971603 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary gland scintigraphy scoring system
Number of subjects: 124
Study 11084187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (15 mg for 8 weeks, then 10 mg for 3 weeks)
Number of subjects: 250
Study 11084187 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 250
Study 11084187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 250
Study 8780082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 MU of HLBI for 28 days
Number of subjects: 48
Study 8780082 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 MU of HLBI for 28 days
Number of subjects: 48
Study 8780082 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 MU of HLBI for 28 days
Number of subjects: 48
Study 8780082 — intervention group
Group type: COMPARATOR
Intervention: 3.0 MU of HLBI
Number of subjects: 48
Study 1281015 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT (nafamostat mesilate) 2 mg/kg/hr during CPB and 0.2 mg/kg/hr before and after CPB
Number of subjects: 30
Study 1281015 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT (nafamostat mesilate)
Number of subjects: 30
Study 6146752 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily for 14 days)
Number of subjects: 43
Study 6146752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31493695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with advice
Number of subjects: 240
Study 31493695 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 240
Study 28754067 — intervention group
Group type: EXPERIMENTAL
Intervention: Online simulation with role‐playing with emotionally responsive virtual patients
Number of subjects: 227
Study 28754067 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 227
Study 27098971 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, multifaceted package of interventions including delayed prescribing, patient decision aids, communication training, commitment to a practice prescribing policy for antibiotics, patient information leaflet, and near patient testing with C-reactive protein.
Number of subjects: 28
Study 27098971 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice without the intervention).
Number of subjects: 28
Study 27098971 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with general practitioners and practice staff from the intervention practices.
Number of subjects: 28
Study 27098971 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation of the intervention package.
Number of subjects: 28
Study 24633725 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy (listening)
Number of subjects: 527
Study 24633725 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy (reading)
Number of subjects: 527
Study 24633725 — intervention group
Group type: COMPARATOR
Intervention: Pap testing adherence
Number of subjects: 527
Study 22041253 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO (Dysport) at 2.5:1.0 U
Number of subjects: 59
Study 22041253 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO (Dysport) at 2.0:1.0 U
Number of subjects: 59
Study 22041253 — intervention group
Group type: COMPARATOR
Intervention: ONA (Botox) at 2.5:1.0 U
Number of subjects: 59
Study 22041253 — intervention group
Group type: COMPARATOR
Intervention: ONA (Botox) at 2.0:1.0 U
Number of subjects: 59
Study 20466698 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic impregnated catheters (Bactiseal)
Number of subjects: 184
Study 20466698 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheters with systemic antibiotics
Number of subjects: 184
Study 18361280 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental counseling and medical care for selective and restrictive children without growth retardation
Number of subjects: 0